Tous Actualités
Suivre
Abonner Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals Announces Acquisition of Worldwide Rights to Amphotec(R)/Amphocil(R)

Cranberry Township, Pennsylvania (ots/PRNewswire)

Three Rivers
Pharmaceuticals, LLC announced today that it has completed the
acquisition of worldwide ownership of Amphotec(R)/Amphocil(R)
(amphotericin B cholesteryl sulfate complex for injection) from
InterMune, Inc. (Nasdaq: ITMN). Amphotec is indicated for the
treatment of invasive aspergillosis, a fungal infection that occurs
in immunocompromised patients. Financial terms of the agreement,
which was signed and executed on May 20, 2005, were not disclosed.
"Three Rivers Pharmaceuticals is very pleased to be acquiring
Amphotec from InterMune," stated Donald J. Kerrish, RPh, President
and CEO of Three Rivers Pharmaceuticals. "This product is a welcome
addition to our offering of specialty pharmaceuticals and will allow
Three Rivers to continue its commitment to providing the highest
standards of quality and customer care."
"Because invasive aspergillosis falls outside of InterMune's two
areas of therapeutic focus, hepatology and pulmonology, we decided it
was in the best interest of both shareholders and patients to divest
this product," stated Dan Welch, InterMune's President and CEO. "We
believe Three Rivers Pharmaceuticals has the right portfolio and
areas of expertise to fully and successfully commercialize this
product."
About Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals is a privately owned company located
in Cranberry Township, PA. Three Rivers Pharmaceuticals' mission is
to develop and market specialty prescription drugs for diseases that
have a significant national and worldwide impact. The company is
dedicated to providing public education, disease state management
programs, and improving patient access to high quality, lower cost
pharmaceutical products. For additional information about Three
Rivers Pharmaceuticals, please visit www.3riverspharma.com .
About InterMune
InterMune is a biopharmaceutical company focused on developing and
commercializing innovative therapies in hepatology and pulmonology.
In addition to the currently marketed product indicated for the
treatment of chronic hepatitis C virus (HCV) infections,
three-times-a-week Infergen(R) (interferon alfacon-1), InterMune has
a broad and deep late-stage product portfolio addressing HCV
infections, particularly nonresponders, or those patients who do not
respond to first-line therapy, and idiopathic pulmonary fibrosis
(IPF). Leading the hepatology portfolio is the DIRECT Trial, a Phase
III study of daily Infergen plus ribavirin, and a Phase IIb trial of
daily Infergen plus Actimmune(R) (interferon gamma-1b) with and
without ribavirin for the treatment of HCV patients who do not
respond to first-line therapy. In addition, InterMune has an early
stage small molecule program targeted at the HCV protease. The
pulmonology portfolio includes pirfenidone and Actimmune. Pirfenidone
is being developed for the treatment of IPF. Actimmune is being
investigated in the INSPIRE Trial, a Phase III study in patients with
IPF. For additional information about InterMune and its development
pipeline, please visit www.intermune.com .
Web site: http://www.3riverspharma.com
              http://www.intermune.com

Contact:

Paul F. Fagan, Esq., Executive Vice-President and General Counsel of
Three Rivers Pharmaceuticals, +1-800-405-8506, or
pfagan@3riverspharma.com